002019 Yifan Pharmaceutical
- 13.88
- +0.15+1.09%
Yifan Pharmaceutical News
Yifan Pharmaceutical Unit Gets Authorization to Sell Circulation Supplement in Singapore
Yifan Pharmaceutical's (SHE:002019) unit, SciGen, received approval from Singapore's Health Sciences Authority to register and market its Ginkgo leaf pills in the city-state, according to a filing wit
Express News | Yifan Pharmaceutical: Ginkgo Biloba Pills Obtain Registration Approval in Singapore
Yifan Pharmaceutical (002019.SZ): Diet drug products are currently in the preclinical research stage
Gelonghui, May 8, 丨 Yifan Pharmaceutical (002019.SZ) held a performance briefing on May 7, 2024 to discuss “Does the company have diet medicine products?” The company replied that the company's diet drug products are currently in the pre-clinical research stage.
Yifan Pharmaceutical (002019.SZ): Heroda is expected to achieve annual revenue of 500 to 1 billion yuan
Gelonghui, May 8, 丨 Yifan Pharmaceutical (002019.SZ) held a performance briefing on May 7, 2024 to discuss “How much revenue is Heroda expected to contribute each year?” The company replied that according to the current sales situation, it is expected to achieve annual revenue of 500 to 1 billion yuan.
Yifan Pharmaceutical (002019.SZ): The Hangzhou production base is expected to have some production capacity between the end of 2024 and the first quarter of 2025
Gelonghui, May 8, 丨 Yifan Pharmaceutical (002019.SZ) held a performance briefing on May 7, 2024, to discuss “What stage has the Hangzhou Synthetic Biology Industrial Park reached? Can the first phase be tested?” The company replied that the Hangzhou production base is under construction according to the plan and is expected to have some production capacity between the end of 2024 and the first quarter of 2025.
Express News | Yifan Pharmaceutical: The first production line of the synthetic biology project will be completed as soon as the end of the year
Express News | Yifan Pharmaceutical: Yilishu's April shipments have surpassed Q1 and H1 performance is expected to grow year-on-year
Yifan Pharmaceutical (002019): Proprietary formulations and innovative drugs have entered the release cycle, and the trend of reversal in performance is clear
Incident: The company released its 2023 annual report, achieved operating income of 4,068 billion yuan (+6.03%) in 2023, and net profit attributable to shareholders of listed companies was -551 million yuan (-388.19%), not after deduction
Yifan Pharmaceutical (002019): The risk of impairment has been cleared, and the inflection point of significant growth of its own products has arrived
Incident: April 20, 2023, the company released its 2023 annual report. In 2023, the company achieved revenue of 4,068 billion yuan, an increase of 6.03% over the previous year; net profit to mother was 551 million yuan. April 2, 2023
Yifan Pharmaceutical (002019): 2023 results are in line with expectations, and both revenue and profit growth accelerated in 2024Q1
Incident The company issued an announcement for 2023, with revenue of 4,068 billion yuan, up 6.03% year on year; net profit due to mother - 551 million yuan, up 388.19% year on year; net profit not attributable to mother - 533 million yuan, year on year
Yifan Pharmaceutical (002019) Quarterly Report Review: The inflection point of performance has reached a rapid growth rate that exceeds market expectations and the growth of the main pharmaceutical industry is driving volume
The 2024 quarterly report was released. The company achieved operating income of 1.3 billion yuan (+41.28% year-on-year, same below) and net profit to mother of 146 million yuan (+125.55%) in Q1 2024, after deducting net profit of non-attributable net profit1
Yifan Unit's Allergy Drug Passes China Regulatory Test, Stock Price Jumps
Yifan Pharmaceutical (SHE:002019) unit Sichuan Defeng Pharmaceutical's emestine fumarate sustained-release capsules passed the consistency evaluation by China's National Medical Products Administratio
Yifan Pharmaceutical's Unit Gets Nod to Register Nimodipine Injection
Yifan Pharmaceutical's (SHE:002019) unit, Liaoning Yifan Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its nimodipine injection, th
Three Drugs of Yifan Pharmaceutical's Unit Placed in China's Centralized Procurement
Three drugs produced by Yifan Pharmaceutical's (SHE:002019) unit, Hefei Yifan Biopharmaceutical, were included in China's National Centralized Drug Procurement, the company said in its filing on the S
Pacific released a research report on April 25 stating that Yifan Pharmaceutical (002019.SZ) was given a purchase rating, and the target price was 18.80 yuan. The main reasons for the rating include: 1) Q1 performance exceeded expectations and formulation
Pacific released a research report on April 25 stating that Yifan Pharmaceutical (002019.SZ) was given a purchase rating, and the target price was 18.80 yuan. The main reasons for the rating include: 1) Q1 performance exceeded expectations and formulation revenue grew rapidly; 2) increased profitability and good cost control; 3) innovative transformation and implementation overseas to meet the new growth cycle. (Mainichi Keizai Shimbun)
Yifan Pharmaceutical (002019): Q1 performance exceeds expectations, lightweight and looks forward to high growth
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved operating income of 4.07 billion yuan, an increase of 6% over the previous year; realized net profit of 550 million yuan, a year-on-year decrease of 388.2%;
Express News | Yifan Pharmaceutical: Net profit from mother in the first quarter was 146 million yuan, an increase of 125.55% over the previous year
Yifan Pharmaceutical (002019.SZ): The disclosure period for the first quarter report was changed to April 24
Gelonghui, April 22丨Yifan Pharmaceutical (002019.SZ) announced that the original scheduled disclosure period for the “2024 First Quarter Report” was April 30, 2024. Now that the preparation of the “2024 First Quarter Report” has been completed ahead of schedule, it has been decided to change the disclosure period of the company's “2024 First Quarter Report” to April 24, 2024.
Pacific released a research report on April 22 stating that Yifan Pharmaceutical (002019.SZ) was given a purchase rating. The main reasons for the rating include: 1) the main business is growing steadily, and the share of pharmaceutical-owned products con
Pacific released a research report on April 22 stating that Yifan Pharmaceutical (002019.SZ) was given a purchase rating. The main reasons for the rating include: 1) the main business is growing steadily, and the share of pharmaceutical-owned products continues to rise; 2) the pharmaceutical business has ushered in a harvest period, driving rapid growth in performance; 3) the initial implementation of innovation and transformation, and the amount of Lilac is imminent. (Mainichi Keizai Shimbun)
Yifan Pharmaceutical (002019): After deducting impairment, it is lightweight and optimistic about the global release of innovative products
Incident: On April 20, 2024, the company released its 2023 annual report. In 2023, the company achieved revenue of 4,068 billion yuan, an increase of 6.03% over the previous year, and net profit to mother was -551 million yuan, the same as last year
Analysis
Price Target
No Data
